Karyopharm Therapeutics Inc. business relationships
Companies named in Karyopharm Therapeutics Inc.’s 10-K filed 2026-02-13, and public companies whose annual reports name Karyopharm Therapeutics Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Karyopharm Therapeutics Inc.’s annual report 2
“Further, in connection with the XPORT-EC-042 Trial, we entered into a global collaboration with Foundation Medicine, Inc. to develop FoundationOne ® CDx, a tissue-based next generation sequencing test to identify and enroll patients whose tumors are TP53 wild-type.” SEC filing
“In December 2020, we entered into an exclusive distribution agreement for the commercialization of XPOVIO in Canada with FORUS Therapeutics Inc. ("FORUS"), a Canadian biopharmaceutical company.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.